Introduction
Gliomas are the most common primary intracranial tumor overall and are often associated with a poor prognosis depending on the tumor grade (Central Brain Tumor Registry of the United States, 2011). Currently, glial tumors are divided into four tumor grades (grades I-IV) based primarily on histological features (Louis et al., 2007) . Low-grade gliomas such as grade I tumors can be curable with surgery; and when grade II tumors are treated with surgery combined with drug therapy, a 7-10 years median survival can be achieved depending on tumor and clinical factors (Cavaliere et al., 2005) . However, as much as 70% of low-grade gliomas undergo malignant transformation over time (Furnari et al., 2007) . High-grade gliomas (that is, anaplastic astrocytomas, grade III; glioblastoma multiforme (GBM), grade IV) are highly proliferative tumors that diffusely infiltrate into the normal brain parenchyma making total resection practically impossible. These high-grade gliomas are much more resistant to therapy than their lower grade counterparts.
The challenge of improving therapeutic outcomes for GBM patients is evidenced in a 5-year survival of o10% (Stupp et al., 2009 ). In the Western world, most patients diagnosed with GBM do not die of untreated gliomas; rather they die of gliomas that recur following therapy. Hence, post-surgical therapy is sufficiently prevalent that its effects can be considered part of the disease itself. Today, glioma post-surgical standard of care therapy consists of radiation and temozolomide as antineoplastic therapy and dexamethasone (DEX) for neurological symptomatic relief. More recently, the antibody to vascular endothelial growth factor (VEGF), bevacizumab, is being used more often at tumor recurrence. As the standard of care therapy modifies the course of the disease, it is likely that this therapy has an effect on both the tumor cells themselves and the various cells that contribute to the tumor stroma.
The relevance of the tumor stroma to glioma maintenance has recently gained a great deal of attention and the various cell types that contribute to the tumor stroma have been implicated in producing products that support the proliferation and migration of glioma cells (Charles et al., 2011) . One intriguing possibility is that tumor stromal cells or their products may be reasonable therapeutic targets in the management of this disease. In addition, it is likely that current therapies that are used to treat glial tumors may alter the tumor stroma in a manner that affects the therapy resistant phenotype observed at tumor recurrence. Understanding how current standard therapy affects the biology of the tumor and the tumor stroma can provide insight into the mechanisms that are important to the inhibition of tumor growth as well as the biology of recurrent tumors. In this review, we will discuss what is known about the characteristics of GBMs and the tumor stroma as well as review what is known (and unknown) about how current standard therapy effects them.
Glioblastomas are molecularly heterogeneous tumors
High-grade gliomas are composed of groups of distinctly different subtypes that can be distinguished by histological, and more recently, by molecular characteristics. Histologically, GBMs have hallmarks of vascular and uncontrolled cellular proliferation, diffuse infiltration, pseudopallisading necrosis and hemorrhage (Folkes et al., 2008; Rong et al., 2006) . With the recent identification of molecular signatures of GBM, the traditional brain tumor classification system based primarily on histology may well be on the verge of transformation. It is likely that the histological and molecular subclasses will be used together in the future to better classify these tumors to provide a more robust system of stratifying glioma with a goal of achieving optimal therapeutic outcomes.
Patterns of gene and protein expression, somatic mutations and copy number alterations have been used to categorize GBMs into distinct subclasses based on stages of neuroglial development (that is, proneural, classical, mesenchymal; Phillips et al., 2006; Brennan et al., 2009; Verhaak et al., 2010; refer to Huse et al. (2011) for a complete review). For example, abnormalities in receptor tyrosine kinases and their ligands are common events in GBM. The proneural subtype is primarily defined by elevated platelet-derived growth factor (PDGF) signaling through PDGFRa amplification or mutation or by PDGFb overexpression, whereas the classical subtype is defined by epidermal growth factor receptor (EGFR) overexpression. Aberrations in components of the RAS-MAPK (GTPase activating protein-mitogen activated protein kinase) signal transduction pathway are also frequently observed in GBM. The tumor suppressor, neurofibromatosis-1 (NF1), indirectly inactivates RAS; and loss of NF1 defines the mesenchymal subtype.
In reality, however, many of these aberrations occur in each of the subclasses, albeit more or less frequently. Elevations in PDGF signaling are observed in B30% of GBMs, whereas amplification of the EGFR is observed in B45% making EGFR the most frequent receptor tyrosine kinase molecular anomaly (Huse et al., 2011) . The constitutively active variant of EGFR (EGFRvIII, characterized by an in-frame deletion of the extracellular domain) occurs commonly along with receptor amplification (Libermann et al., 1985; Wong et al., 1992; Frederick et al., 2000) . Loss of function of the p53 and RB tumor suppressors by mutation, deletion or copy number alteration (in the case of MDM2 and CDK4, respectively) is observed in more than 75% of GBMs (Network, 2008) . Presumably, further molecular analysis of these tumors will clarify the number of biologically homogeneous tumor subtypes. At this point, the two subtypes that appear to be the most robust across multiple data sets are the proneural and mesenchymal (Huse et al., 2011) .
From a clinical standpoint, proneural tumors occur in younger patients and consist of additional molecular alterations characteristic of secondary grade IV lesions (Phillips et al., 2006; Verhaak et al., 2010) . Conversely, mesenchymal tumors are predominately primary GBMs and the mesenchymal signature is consistent with increased angiogenesis, more aggressive disease and thus is associated with poor outcome in patients (Huse et al., 2011) . Another molecular factor that has been found to have prognostic significance is the isocitrate dehydrogenase (IDH) gene. Point mutations in IDH1 and IDH2 are found frequently in lower grade gliomas and comprise the subset of proneural GBM with the best prognosis (Yan et al., 2009) . Currently, the most well-known and proven molecular aberration that can predict the response to the current standard of care cytotoxic drug therapy (temozolomide) is the methylation status of the methylguanine DNA methyltransferase (MGMT) promoter. Patients having a methylated MGMT promoter respond much better to standard therapy than those with an unmethylated promoter (median survival 21.7 months versus 12.7 months, respectively; Hegi et al., 2005) .
Although, molecular studies have shed tremendous light on this very complex disease many unanswered questions remain about the biology of glioma. Fortunately, histologically and genetically relevant mouse models of GBM that correspond with the molecular subtypes have already been developed and these models validate the significance of signal transduction pathways in gliomagenesis (Zhu et al., 2009; Hambardzumyan et al., 2011; Jones and Holland, 2011) . There are several short latency and high penetrant models that can be used to better understand the biology of glioma and are essential tools for testing novel drugs against this terminal disease.
The tumor stroma and the perivascular niche Tumor tissue that is surgically resected from patients not only contains neoplastic cells but also contains nontransformed stromal cells. There are several cell types that make up the tumor stroma and can contribute to the biology of glioma to include astrocytes, endothelial cells, pericytes and cells involved in the immune response (that is, microglia and T-lymphocytes; Daginakatte and Gutmann, 2007; Charles et al., 2011) . The tumor microenvironment is enriched with soluble factors secreted by these cells. These factors mediate the cross talk between the tumor and stromal cells promoting tumor progression and invasion (Figure 1) . Another cell population found in the perivascular niche (PVN) is the glioma stem-like cells. Below we discuss how these tumor-associated cells may contribute to glioma maintenance. Knowledge of how these cells interact with each other can shed light on the direct and indirect effects of standard therapy on each cell type and, more importantly, how these effects may ultimately influence the biology of glioma.
Astrocytes
In a general sense, astrocytes are responsible for providing nutritional support and maintaining homeostasis in the brain (Wilhelmsson et al., 2006) . Astrocytes make up the vast majority of non-neuronal cells in the brain accounting for B50% of the brain cortex. In the PVN, astrocytes are closely associated with the endothelia and are involved in maintaining the bloodbrain barrier . Tumor-associated astrocytes have a role in tumor maintenance and are believed to be involved in promoting cell invasion and proliferation through the production of neurotrophic factors (that is, chemokine ligand-12 (CXCL12), transforming growth factor-a (TGFa) and glial cell-derived neurotrophic factor; Hoelzinger et al., 2007;  Table 1 ; Figure 1 ). TGFa is associated with tumor invasion (Kaur et al., 2005) and its expression has been shown to be increased in glioma cells in the presence of the mutated EGF receptor, EGFRvIII (Ramnarain et al., 2006) . Glial cell-derived neurotrophic factor and its receptor (GDNFRa) are overexpressed in human glioma and high expression in glioma cell lines leads to an increase in cell migration (Wiesenhofer et al., 2000) . CXCL12 (also known as stromal cell-derived factor-1) is believed to have a role in stimulating glioma cell proliferation by interacting with its receptor, chemokine receptor type-4 (CXCR4; Bajetto et al., 1999a, b; Barbero et al., 2002) . Increased expression of CXCL12 has been shown to increase tumor invasiveness in vitro (Hong et al., 2006) . Another signaling pathway associated with tumor invasiveness involves the plasminogen/plasmin pathway. Glioma cells can secrete plasminogen, which interacts with the astrocyte products urokinase-type plasminogen activator (uPA)/uPA receptor resulting in plasmin production (Le et al., 2003) . The inactive matrix metalloprotease-2, also secreted by astrocytes, can then be converted to active MMP-2 by plasmin-promoting tumor invasion.
Endothelial cells
Endothelial cells in the brain line the lumen of blood vessels forming the blood-brain barrier. These cells can secrete a variety of proinflammatory factors (for example, interleukin (IL)-10, IL-6 and tumor necrosis factor a (TNFa)) that can dictate vascular leakiness (Verma et al., 2006;  Table 1 ) and can also secrete factors that can increase stem cell proliferation such as Standard of care therapy in glioma TS Jones and EC Holland brain-derived neurotrophic factor and pigment epithelium-derived factor (Leventhal et al., 1999; RamirezCastillejo et al., 2006) . In glioma, endothelial cells drive the stem cell phenotype of tumor stem-like cells located in the PVN (Calabrese et al., 2007) through nitric oxide (NO) production (Calabrese et al., 2007; Charles et al., 2010) . Endothelia nitric oxide synthase expressed by tumor-associated endothelial cells can produce NO, which can activate the Notch pathway and promote a stem cell phenotype (Charles et al., 2010) . In this study, a proneural mouse model of glioma was used to demonstrate that increased endothelia NO synthase expression was specifically localized to the tumor vascular endothelium; and cells coexpressing Nestin and the Notch intracellular domain were closely associated to the tumor endothelial cells. The Notch pathway is important to cell differentiation and has been linked to normal and glioma stem cell biology (Baron, 2003; Wang et al., 2009) . Notch signaling can also influence chemoresistance by increasing drug efflux through ABCG2 (Fan et al., 2006; Bhattacharya et al., 2007) . As discussed below, endothelial cell interactions with pericytes and brain tumor stem-like cells can also promote angiogenesis through PDGF and VEGFC signaling, respectively.
Pericytes and vascular smooth muscle cells
In addition to endothelial cells, pericytes can have a key role in microvascular proliferation. Pericytes and vascular smooth muscle cells (collectively termed mural cells) function to provide structural support to the vasculature and maintain hemodynamic stability (Cleaver and Melton, 2003) . These mural cell types help to stabilize the vasculature within the normal brain as well as the tumor environment by covering the outer layer of the vascular tube (Ozerdem and Stallcup, 2004; DiazFlores et al., 2009) . Interactions between endothelial cells and mural cells can promote angiogenesis. For example, during blood vessel formation, pericytes can be recruited by endothelial cells through PDGF paracrine signaling (Gerhardt and Betsholtz, 2003; Betsholtz, 2004) . Endothelial cells that express PDGFb can recruit pericytes and vascular smooth muscle cells to support Abbreviations: ABCB, ABCG2, ATP-binding cassette sub-family B and G; Ang2, angiotensin 2; BDNF, brain-derived neurotrophic factor; CSF, colony-stimulating factor; CXCL12, chemokine ligand-12; eNOS, endothelial nitric oxide synthase; GDNF, glial cell-derived neurotrophic factor; HGF, hepatocyte growth factor; IL, interleukin; MCP, complement regulatory protein; MMP, matrix metalloproteinase; MIC-1 or GDF15, growth differentiation factor; NO, nitric oxide; proMMP-2, inactive MMP-2; PEDF, pigment epithelium-derived factor; PDGF, platelet-derived growth factor; SDF-1, stromal cell-derived factor; TGF, transforming growth factor; TNFa, tumor necrosis factor a; Tie2, tyrosine kinase, endothelial; uPA, urokinase-type plasminogen activator; uPAR, uPA receptor; VEGF, vascular endothelial growth factor.
and stabilize the blood vessels during development (Hellstrom et al., 1999) . A study that inhibited PDGF function in endothelial cells showed a decrease in pericyte recruitment emphasizing the importance of PDGF signaling in promoting stable vessel formation (Enge et al., 2002; Bjarnegard et al., 2004) . Another pericyte-endothelial cell interaction involves the Tie2 receptor expressed by endothelial cells and its ligand Ang1 expressed by adjacent pericytes. Genetically engineered mice deficient for Tie2 and Ang1 have been shown to have defective angiogenesis and pericyte coverage (Sato et al., 1995; Suri et al., 1996) .
Microglia
Microglia, the resident macrophages of the brain, make up the dominant glioma-associated immune cells. These cells can possess a 'glioma-promoting' phenotype or 'glioma inhibitory' phenotype depending on the factors that they secrete. Under stressful conditions (that is, tissue damage, irritants) microglia can secrete cytokines that promote inflammation, cytotoxicity and phagocytosis (Hanisch, 2002) . However, glioma cells can secrete chemoattractants to recruit microglia to the tumor environment transforming them to a protumorigenic phenotype (Graeber et al., 2002 ; Table 1 ). Protumorigenic microglia do not produce inflammatory cytokines, but instead produce factors that promote a more permissive tumor environment (Weissenberger et al., 2004; Yeh et al., 2011 ; Figure 1 ). Tumor cells can secrete several anti-inflammatory factors including TGFb, which can inhibit microglia activation and proliferation (Suzumura et al., 1993; Suzuki et al., 2008) . In addition, brain tumor stem-like cells can act on microglia and induce the secretion of cytokines (for example, TGFb1, MIC-1, sCSF-1) that promote an immunosuppressive phenotype (Wu et al., 2010) . In addition, it has been shown that soluble factors secreted by tumor cells can cause the upregulation of matrix metalloproteinase-14 (MMP-14) expression in microglia (Markovic et al., 2009) . MMP-14 can activate inactive matrix metalloprotease-2 secreted by glioma cells and lead to the break down of the extracellular matrix. Results from in vitro studies support the idea that microglia can promote tumor invasion and growth (Bettinger et al., 2002; Markovic et al., 2005) . Perhaps the most convincing evidence of the importance of microglia to glioma formation is from in vivo studies that have shown that tumor cell growth is inhibited in microglia-deficient glioma mouse models (Daginakatte and Gutmann, 2007; Markovic et al., 2009) . These findings suggest that therapies that target glioma-associated microglia may be promising antitumor agents.
Glioma stem-like cells
Although there has been much debate about the existence and role of glioma stem cells, it has been suggested that cells with stem cell character may be the cell population involved in some recurrence (Calabrese et al., 2007) . These cells exhibit a stem-like character through their ability to self-renew, express markers of normal stem cells (for example, CD133 and Nestin) and generate heterogeneous tumors upon reimplantation. These cells tend to be located in the tumor perivascular region secrete elevated levels of VEGF and generate highly vascularized gliomas upon implantation into mice (Bao et al., 2006b ). As discussed above, cells located in the tumor PVN can secrete signaling factors that promote the stem cell-like phenotype (Calabrese et al., 2007; Hambardzumyan et al., 2008; Charles et al., 2010) . These tumor stem-like cells tend to be located around the rim of necrosis and adjacent to the endothelial cells in the vascular space (Calabrese et al., 2007) . As mentioned previously, endothelial cells can produce NO by endothelia NO synthase and the stem cell character of this population is reinforced by NO signaling (Charles et al., 2010) . Microglia can also produce NO by inducible nitric oxide synthase (Minghetti and Levi, 1998; Charles et al., 2010) and thus may contribute to the stem-like cell phenotype. However, the potential contribution of microglia produced NO to the tumor stem cell phenotype that has yet to be explored. It has also been shown that glioma stem-like cells express multi-drug resistance proteins such as ABCG2 and P-gp (Lu and Shervington, 2008; Bleau et al., 2009; Wang et al., 2010) ; hence, these cells tend to be highly resistant to cytotoxic drug therapy (Charles and Holland, 2009 (Dix et al., 1999) . Signaling through CXCL12-CXCR4 is known to recruit Tregs to bone marrow and may also be involved in the recruitment of Tregs to brain tumors (Zhou et al., 2002; Grauer et al., 2007) . These cells are believed to promote a permissive tumor environment by suppressing the immune response. One study used a mouse model of glioma to show that depletion of Tregs can significantly prolong survival (El Andaloussi et al., 2006) . Although T-lymphocytes have long been known to invade gliomas there has been little understanding of the clinical significance of this finding. However, in a recent study it was shown that high infiltration of T-cells (effecter, cytotoxic, helper) was associated with better outcomes in patients with primary GBM and was directly correlated with ICAM-1 (intracellular adhesion molecule-1) expression on endothelial cells (Lohr et al., 2011) . It was also found that TGFb downregulated CAM expression and the transmigration of autologous T-cells in vitro. These findings suggest that peripheral Tlymphocytes are an important component of the immune response in glioma and that increasing ICAM expression by inhibiting TGFb function may help to enhance the T-cell response.
The effect of standard therapy on tumor and stromal cells in glioma Several studies have discussed the effects of standard therapy on tumor cells and, more recently, on the tumor stem-like cell population. With increasing evidence of the role of the stromal cell population in promoting tumor growth and the tumor stem-like cell phenotype, the effect of glioma therapy on stromal cells must also be understood (Figure 2 ). There are many reviews that discuss experimental therapies currently being tested in glioma management. In this review, we will focus specifically on the standard of care therapy that is commonly used in treatment today and its effects on the tumor stromal cells. In this section, we summarize what is now known about the effects of standard therapy on the tumor stromal cell populations discussed above.
Radiation therapy
For over 50 years, radiation therapy has remained the backbone of standard therapy for the treatment of malignant glioma. Radiation therapy is typically given after surgical resection of the brain tumor mass (and concurrent with cytotoxic drug therapy) to eradicate the residual populations of neoplastic cells that are left behind after surgery. Radiation is very effective at eradiating bulk tumor while radiation exposure to other cell types residing in the tumor environment promotes inflammation and cell proliferation. Radiation therapy can induce microglia to precipitate a rapid inflammatory Figure 2 The effect of standard therapy on glioma and stromal cells. Tumor stromal cells are intimately located near the vasculature and interspersed throughout the tumor. Radiation (IR) is effective at eradiating bulk tumor and can induce astrocytes and microglia to precipitate a rapid inflammatory response by upregulating several cytokines. Microglia can also display an increase in the expression of growth factors involved in stem cell maintenance post IR and glioma stem-like cells can be resistant to radiation therapy. Temozolomide (TMZ) is a alkylator-like agent that exerts its antitumor effect by interfering with DNA replication. Glioma stem-like cells can be resistant to TMZ partly due to elevated MGMT expression and multi-drug resistant protein expression. Bevacizumab (BVZ) is a monoclonal antibody against VEGF and inhibits angiogenesis by blocking ligand binding. BVZ therapy may induce a more hypoxic tumor microenvironment potentially increasing tumor invasion into the normal brain parenchyma. Dexamethasone (DEX) is believed to function by decreasing vascular leakiness through effects on endothelial cells but could also function by inhibiting microglia. Microglial and endothelial cell populations contribute to glioma maintenance and are thought to be involved in the corticosteroid response to cerebral edema. However, the mechanism of exactly how DEX exerts its effects remains unknown. Many questions remain as to how standard therapy directly or indirectly affects the various stromal cell types.
response by upregulating several cytokines, including TNFa, TNFb, IL-1a, IL-1b, IL-6 and Gro/KC (Kureshi et al., 1994; Kyrkanides et al., 1999; Kim et al., 2002; Hwang et al., 2006; Kalm et al., 2009) . In astrocytes, radiation exposure can induce a proinflammatory response by increasing TNF production, which can enhance the antitumor effect (Chiang and McBride, 1991) . A similar proinflammatory microglial response can be observed post irradiation through increases in TNFa and TNFb. Irradiation can also increase the number of amoeboid microglia compared with controls in the rat brain (Hellstrom et al., 2011) . In addition, microglia can display an increase in gene expression of growth factors involved in stem cell maintenance (FGF2, LIF and PDGFb) post irradiation exposure (Hellstrom et al., 2011 ). An increase in factors involved in stem cell maintenance may have a role in driving the glioma stemlike cell phenotype. Brain tumor stem-like cells can be resistant to radiation therapy and radiation has been shown to increase the CD133 þ cell population both in vitro and in vivo studies (Bao et al., 2006a) . In a medulloblastoma model, a relative sparing of Nestinexpressing cells in the PVN region after radiation exposure can be observed (Hambardzumyan et al., 2008) . These findings support the notion that the brain tumor stem cell population is responsible (at least in part) for radioresistance in glioma.
Temozolomide
Most patients diagnosed with a GBM are treated with temozolomide, and the vast majority of research on this drug has focused on its effects on the tumor cells per se.
Temozolomide is a alkylator-like agent that exerts its antitumor effect by interfering with DNA replication. Currently, one of the best predictors of the tumor cell response to temozolomide is the methylation status of the MGMT promoter. In some patients, a methylated MGMT promoter is associated with a better therapeutic response to temozolomide and longer survival as compared with patients with an unmethylated promoter status (Stupp et al., 2009) . Indeed, there remains a large percentage of patients who have a methylated MGMT promoter status and do not respond to temozolomide. Clinical studies have shown that B50% of these patients die within the first 2 years of therapy (Stupp et al., 2009) . Glioma stem-like cells are resistant to temozolomide partly due to elevated MGMT expression (Bleau et al., 2009) . Promoter methylation has been shown to be concordant in GBM samples and matching glioma stem cells (Sciuscio et al., 2011) ; although the effectiveness of temozolomide is not concordant between matched samples. Studies have shown that in vitro exposure of neural stem cells and glioma stem cells to temozolomide can cause cell growth inhibition in the neural stem cell population but not in the glioma stem cells (Gong et al., 2011) . A mechanism of the glioma stem cell resistant phenotype is the expression of multi-drug resistant proteins. Glioma stem cells express ABCG2 and temozolomide exposure can actually increase the glioma stem cell side population suggesting that treatment can increase their resistance to drug therapy. In fact, exposing these cells to temozolomide in culture results in more aggressive and treatment resistant tumors when implanted into mice (Bleau et al., 2009 ). There has been some work that has looked at the effect of temozolomide on a few stromal cell types. Although temozolomide can be effective at eradicating tumor cells, a few studies have found that it has neither effect on microglial and endothelial cell growth and viability nor is there an effect on endothelial cell migration (Vairano et al., 2004; Virrey et al., 2009) . However, there has been some work on the effect of temozolomide stromal cell products. One study found that Tregs isolated from patients with GBM had higher expression of a CCL2 receptor (CCR4) than did Tregs from normal patients (Jordan et al., 2008) suggesting that CCL2 expressed by GBM may be the chemoattractant for Tregs migration. In an experimental rodent model of glioma, treatment with a low dose of temozolomide resulted in a decreased level of Tregs infiltration and longer survival (Banissi et al., 2009) . Indeed, the literature is lacking in studies that investigate whether temozolomide has a direct or indirect effect on other stromal cell types or their products and whether these effects induce a glioma inhibitory or glioma-promoting response.
Bevacizumab
Bevacizumab is an example of a therapy that is targeted toward the tumor stroma. With increasing frequency bevacizumab is given to patients at tumor recurrence and is now being tested for its utility in primary disease (Arko et al., 2010) . Unlike temozolomide and radiation therapy, bevacizumab's primary mode of action is not on the tumor cells but is on the endothelial cells. Bevacizumab is a monoclonal antibody against VEGF and can also affect tumor endothelial progenitor cells by inhibiting their maturation into endothelium , and thus collectively blocking the formation of new blood vessels. It has also been suggested that bevacizumab can normalize blood vessels within the tumor-improving drug delivery from the bloodstream into the brain tumor (Jain, 2005) . GBMs are highly vascularized tumors and bevacizumab therapy may extend survival in some recurrent patients (Zuniga et al., 2009 ). To date, clinical studies that have assessed the benefit of adding bevacizumab to standard therapy in primary GBM have been less impressive (Lai et al., 2011) . However, one study found that combining therapies against endothelial cells and pericytes can result in a synergistic antitumor effect (Bergers et al., 2003) supporting the concept that the use of many drugs directed toward different molecular targets can achieve optimal treatment response.
One adverse consequence of bevacizumab therapy is the induction of a more hypoxic tumor microenvironment potentially favoring a metabolic shift toward glycolysis in tumor cells and increasing tumor invasion into the normal brain parenchyma (Keunen et al., 2011) . Some studies have looked at the effects of hypoxic conditions on stromal cells. Under hypoxic conditions astrocytes have an increased expression of soluble factors involved in angiogenesis and cell migration (that is, VEGF, SCF, CXCL12; Xu et al., 2007) . In addition, astrocytes can secrete factors that can attenuate the antiinflammatory response of microglia caused by a hypoxic environment (Kim et al., 2010) . Further, the molecular signature of tumor stem-like cells within a hypoxic tumor microenvironment implicates HIF2a as a key regulator of the stem cell phenotype (Seidel et al., 2010) . These findings could suggest that by inhibiting the inflammatory response of microglia and stimulating a stem cell phenotype, antiangiogenic therapy may promote the transition to a more aggressive disease. More studies investigating the influence of antiangiogenic therapy on tumor stroma is needed to better understand how it contributes to the biology of glioma.
Dexamethasone
Intracranial tumors can cause significant peritumoral edema leading to debilitating or life-threatening neurological symptoms. Corticosteroids have been used for decades for neurological symptomatic relief with most patients experiencing a dramatic improvement of symptoms (Kofman et al., 1957; Galicich and French, 1961; Gutin, 1975) . However, the mechanism by which DEX exerts its effect and how it influences the biology of the disease is unknown. More importantly, DEX is often ignored as a possible contributor to the biology of glioma, even though it clearly alters the course of the disease. It is believed that the reason patients 'feel better' after corticosteroid treatment is due to the antiinflammatory effects of DEX and its ability to decrease vascular permeability (Rovit and Hagan, 1968; Eisenberg et al., 1970; Ehrenkranz and Posner, 1980) . Microglial and endothelial cell populations have been shown to contribute to glioma biology and are thought to be involved in the corticosteroid response to cerebral edema. In vitro and ex vivo studies suggest that DEX treatment can inhibit the production of inflammatory factors produced by microglia (Ganter et al., 1992) and can also inhibit microglial proliferation (Kiefer and Kreutzberg, 1991; Ganter et al., 1992; Chang and Liu, 2000) . Hence, it is possible that DEX may collaborate with the anti-inflammatory chemokines secreted by glial tumor cells creating a more permissive tumor environment. It is also possible that DEX functions partly through effects on the tumor cells themselves or other cells of the PVN. Some in vivo studies have shown a reduction in tumor size after DEX exposure (Cairncross et al., 1988) ; although no corticosteroid-associated survival benefit has been observed (Green et al., 1983; Watling et al., 1994; Villeneuve et al., 2008) . Whether and how DEX or the other standard of care therapies modify the tumor stroma and contribute to a more permissive tumor environment or possibly tumor recurrence should be studied more closely. The goal of studying the effects of standard therapy on these cell types is to gain insight into what molecular phenotypes are due to the disease itself versus what is being created by drug therapy. It is possible that some therapies that we give to some patients contribute to disease complexity.
Novel approaches targeting the tumor stroma
Currently, there are a number of therapeutic approaches being tested for glioma and some of which are directed toward the brain tumor stroma (refer to Bergers et al. (2003) for a complete review). As discussed above, bevacizumab is the first agent that targets the tumor stroma by binding VEGF ligand and blocking angiocrine signaling, whereas cediranib targets angiocrine signaling through inhibiting VEGFR kinase. Cilegentide is an anti-invasion agent that targets integrins expressed by endothelial cells and is currently in clinical trials for glioma. Agents that target PDGFR not only affect the tumor cells directly but also function by interfering with cell signaling between endothelial cells and pericytes. In addition, a treatment directed toward inhibiting the TGFb receptor I is currently under investigation (Anido et al., 2010) . As previously discussed, TGFb is intimately involved in tumor promotion and progression through tumor-stromal cell interactions.
The cell types of the stroma are critical components of gliomas and they contribute to the biology and resistant phenotype of these tumors substantially. These cell types are clearly affected by the therapies we give but the effects of those therapies on these critical cells are under appreciated. Moreover, these cell types represent potential therapeutic targets in their own right and because of their relative genomic stability they may be less likely to develop resistance than the tumor cells per se.
Summary
According to the Central Brain Tumor Registry, more than 22 000 people are diagnosed with a high-grade glioma in the United States each year (Wen and Kesari, 2008 ; Central Brain Tumor Registry of the United States, 2011). Of these, GBMs are among the most devastating intracranial neoplasms overall and most patients will die within the first 2 years of diagnosis despite aggressive therapy. Until recently, pharmacological therapy for high-grade glioma has remained largely stagnated. There have been a number of primary papers and reviews published over the past several years that discuss the role of signal transduction pathways in gliomagenesis and the potential therapeutic utility of signal transduction inhibitors (Huse and Holland, 2010) . Indeed, a plethora of signal transduction inhibitors have been developed and several are currently being tested in clinical trials for glioma (Arko et al., 2010; Van Meir et al., 2010) . Unfortunately, preliminary findings from many of these trials suggest that these agents have not significantly influenced the course of the disease when compared with standard of care therapy (Arko et al., 2010) . However, the recently defined molecular subclasses of glioma have validated the significance of many of these pathways and may provide a means for employing the use of specific signal transduction inhibitors in patients with a corresponding molecular signature.
Little effort has gone into understanding what our standard of care actually does to the various cell types of these tumors. GBMs are cellularly complex tumors and the treatments that we use can have an effect on many of these cell types. Recognizing that non-neoplastic stromal cells and their products can have an integral role in glioma maintenance, progression and migration, it is important to obtain an understanding of how glioma therapy influences the various cell populations that contribute to the tumor stroma.
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